New approaches for biomarker discovery in lung cancer

Expert Review of Molecular Diagnostics

Volumn 3, Issue 1, 2003, Pages 55-67

  Valle, Rosaura P C ^a   Chavany, Christine ^a   Zhukov, Tatyana A ^b   Jendoubi, Moncef ^a  

^a Milagen Inc   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Biomarkers; Early detection; High throughput; Lung cancer; Polyclonal antibodies; Protein array; Proteomics; Serum markers

Indexed keywords

BIOLOGICAL MARKER; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; POLYCLONAL ANTIBODY; TUMOR MARKER;

BIOASSAY; BLOOD ANALYSIS; BRONCHOSCOPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SCREENING; DIAGNOSTIC TEST; DNA MICROARRAY; EARLY DIAGNOSIS; EUKARYOTE; GENOMICS; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MOLECULAR BIOLOGY; MONITORING; POLYMERASE CHAIN REACTION; PROTEIN DETERMINATION; PROTEOMICS; REVIEW; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SPUTUM CYTODIAGNOSIS;

CHROMOSOME ABERRATIONS; GENES, SUPPRESSOR; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; HUMANS; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; POLYMERASE CHAIN REACTION; PROTEOMICS; SPUTUM; TOMOGRAPHY, SPIRAL COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0037229669     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.3.1.55     Document Type: Review

References (78)

1. Smith RA, Glynn TJ. Epidemiology of lung cancer. Radiol. Clin. North Am. 38, 453-470 (2000).
2. Jemal A, Thomas A, Murray T et al. Cancer statistics. CA Cancer J. Clin. 52, 23-47 (2002). Latest cancer statistics.
3. American Cancer Society, ACS, Facts & Figures 2002. American Cancer Society, Atlanta, GA, USA (2002).
4. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 86, 1867-1876 (1999).
5. Smith RA, Cokkinides V, Von Eschenbar A, et al. American Cancer Society: guidelines for the early detection of cancer. CA Cancer J. Clin. 52, 8-22 (2002).
6. Jett JR. Screening for lung cancer: no longer a taboo subject. J. Clin. Oncol. 20, 1959-1961 (2002).
7. Strauss GM. The Mayo lung cohort: a regression analysis focusing on lung cancer incidence and mortality. J. Clin. Oncol. 20, 1973-1983 (2002).
8. Haura EB. Treatment of advanced nonsmall-cell lung cancer: a review of current randomized clinical trials and an examination of emerging techniques. Cancer Control 8, 326-336 (2001).
9. Schiller JH. Current standards of care in small-cell and nonsmall-cell lung cancer. Oncology 61(Suppl. 1), 3-13 (2001). Chemotherapies cocktails for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
10. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lungs of current and former smokers J. Natl. Cancer Inst. 89 834-836 (1997).
11. Witsuba II, Lam S, Behrens C, et al. Molecular damages in the bronchial epithelium of current and former smokers. J. Natl Cancer Inst. 89, 1966-1973(1997). Comparative losss of heterozygosity (LOH) analysis in smokers and nonsmokers.
12. Mulshine JL, Zhou J, Treston AM, Szabo E, Tockman MS, Cuttitta F. New approaches to the integrated management of early lung cancer. Hematol. Oncol. Clin. North Am. 11, 235-252 (1997).
13. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur. Respir. J. 18, 1059-1068 (2001).
14. Carbone DP. The biology of lung cancer. Semin. Oncol. 24, 388-401 (1997).
15. Tuveson TA, Jacks T. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene 18, 5318-5324 (1999). Molecular analysis of lung cancer and relevance to the animal models.
16. Thun MJ, Lally CA, Flannery JT et al. Cigarette smoking and changes in the histopathology of lung cancer. J. Natl Cancer Inst 89, 1580-1586 (1997).
17. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J. Clin. Oncol. 16, 1207-1217 (1998). Where to refresh roles and functions of oncogenes and tumor-suppressor genes relevant to lung cancer.
18. Nildinski J, Nildinska W, Chyczewski L, Becker HD, Pluygers E. Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications. Eur. J. Cancer Prev. 10, 213-226 (2001).
19. Braithwaite KL, Rabbitts PH. Multistep evolution of lung cancer. Semin. Cancer Biol. 9, 255-265 (1999).
20. Tockman MS. Lung cancer: chemoprevention and intermediate effect markers. IARC Sci. Publ. 154, 257-270 (2001).
21. Hirsch FR, Franklin WA, Gazdar AF, Bunn PA Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin. Cancer Res. 7, 5-22 (2001). Clinical analysis of lung cancer pathology and premalignant lesions.
22. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin. Oncol. 29(Suppl 4), 3-14 (2002).
23. Gazdar AF, Minna JD. Molecular detection of early lung cancer. J. Natl. Cancer Inst. 91, 299-301 (1999).
24. Sidransky D. Molecular detection of lung cancer. In: Lung Cancer. Cox, Hong (Eds). Blackwell Science, Oxford, UK, 253-268 (1998).
25. Tockman MS, Mulshine JL. The early detection of occult lung cancer. Chest Surg. Clin. North Am. 10, 737-749 (2000).
26. Tockman MS. Clinical detection of lung cancer progression markers. J. Cell. Biochem. 25S, 177-184 (1996).
27. Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl Cancer Inst. 91, 332-339 (1999).
28. Esteller M, Sanchez-Cespedes M, Rosell R, Sidranski D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor-suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67-70 (1999).
29. Palmisano WA, Divine KK, Saccomanno G et al. Predicting first-line lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954-5958 (2000).
30. Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U. Detection of microsatellite alterations in plasma DNA of nonsmall cell lung cancer patients: a prospect for early diagnosis. Clin. Cancer Res. 5, 2689-2692 (1999).
31. Zhou J, Mulshine JL, Unsworth EJ et al. Purification and characterization of a protein that permits early detection of lung cancer. J. Biol. Chem. 271, 10760-10766 (1996).
32. Tockman MS, Zhukhov TA, Erozan YS, et al. Antigen retrieval improves hnRNP A2/B1 immunohistochemical localization in premalignant lesions of the lung. In: Clinical and Biological Basis of Lung Cancer Prevention. Martinet Y, Hirsch FR, Martinet N, Vignaud J.-M, Mulshine JL (Eds). Birkhauser Verlag, Basel, Switzerland, 239-246 (1998).
33. Zhou J, Nong L, Wloch M, Zhukov TA, Tockman MS. Expression of early lung cancer detection marker hnRNP A2/B1 and its relation to microsatellite alteration in nonsmall cell lung cancer. Lung Cancer 34, 342-350 (2001).
34. Zhukov TA, Erozan YS, Tockman MS. Sentinel cell for lung cancer. Proceedings of the 14th International Congress of Cytology. Amsterdam, The Netherlands, 352, (2001).
35. Man YG, Martinez A, Avis IM, et al. Phenotypically different cells with heterogenous nuclear ribonucleoprotein A2/B1 overexpression show similar genetic alterations. Am. J. Respir. Cell Mol. Biol. 23, 636-645 (2000).
36. Tockman MS, Mulshine JL, Piantadosi S, et al. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin. Cancer Res. 3, 2237-2246 (1997).
37. Fielding P, Tunbull L, Prime W et al. Heterogenous nuclear ribonucleoprotein A2/B1 upregulation in bronchial lavage specimens: a clinical marker of early lung cancer detection. Clin Cancer Res. 5, 4048-4052 (1999).
38. Sone S, Li F, Yang ZG et al. Results of three-year mass screening program for lung cancer using mobile low-dose spiral computed tomography scanner. Br. J. Cancer 84, 25-32 (2001).
39. Henchke, CI, McCauley DI, Yankelevitz DF, et al. Early lung cancer action project: overall design and findings from baseline screening. Lancet 354, 99-105 (1999).
40. Vazquez MF, Flieder DB. Small peripheral glandular lesions detected by screening CT for lung cancer. A diagnostic dilemma for the pathologist. Radiol. Clin. North Am. 38, 579-89, (2000).
41. Swensen SJ, Jett JR, Sloan JA et al. Screening for lung cancer with low-dose spiral computed tomography. Am. J. Resp. Crit. Care Med. 165, 508-513 (2002).
42. Lam S, Kennedy T, Unger M et al. Localization of bronchial interepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 113, 696-702 (1998).
43. Strauss GM. Prognostic markers in resectable nonsmall cell lung cancer. Hematol. Oncol. Clin. North Am. 11, 409-434 (1997).
44. Reinmuth N, Brandt B, Semik M et al. Prognostic impact of CYFRA 21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 3, 265-270 (2002).
45. Ameral Mendes JJ, Pluygers B. Use of biochemical and molecular biomarkers for cancer risk assessment in humans. In: Perspectives on Biologically Based Cancer Risk Assessment. Cogliano VJ, Luebeck EG, Zapponi GA (Eds). Kluwer Academic / Plenum Publishers, NY, USA, 81-182 (2001).
46. Liu MC, Gelmann EP. P53 mutations: case study of a clinical marker for solid tumors. Semin. Oncol. 29(Suppl. 9), 246-257 (2002).
47. neu expression in human lung cancer adenocarcinomas predict short survival. Cancer Res. 50, 5184-5191 (1990).
48. Hirsch FR, Franklin WA, Bunn PA Jr. Expression of target molecules in lung cancer: challenge for a new treatment paradigm. Semin. Oncol. 29(Suppl 9), 2-8 (2002).
49. Schoemaker DD, Schadt EE, Armour CD et al. Experimental annotation of the human genome using microarray technology. Nature 409, 922-927 (2001).
50. Kallioniemi OP. Biochip technologies in cancer research. Ann. Med. 33, 142-147 (2001). Review of DNA microarray applications in cancer.
51. Young GD, Winokur TS, Cerfolio RJ et al. Differential expression and biodistribution of cytokeratin 18 and desmoplakins in nonsmall cell lung carcinoma subtypes. Lung Cancer 36, 133-141 (2002).
52. Wang T, Fan L, Watanabe Y, McNeill P, Fanger GR, Persing DH, et al. L552S, and alternatively spliced isoform of XAGE-1, is overexpressed in lung adenocarcinoma. Oncogene 20, 7699-7709 (2001).
53. Beer D, Kardia S, Hanash S. Gene expression profiles predict survival of patients with lung adenocarcinoma. Nature Med. 8, 816-824 (2002).
54. Miura K, Bowman E, Simon R et al. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco-smoking and prognosis-related molecular profiles. Cancer Res. 62, 3244-3250 (2002).
55. Simone NL, Bonner RF, Gillespie JW, Emmert-Buck MR, Liotta LA. Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet. 14, 272-76 (1998).
56. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol. Cell Biol. 19, 1720-1730 (1999).
57. Chen G, Gharib TG, Huang CC, Taylor JM et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell Prot. 4, 304-213 (2002).
58. Kapranov P, Cawley SE, Drenkow J, et al. Large-scale transcriptional activity in chromosome 21 and 22. Science 296, 916-919 (2002).
59. Maniatis T, Tasic B. Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature 418, 236-243 (2002). Good review.
60. Rowen L, Young J, Birditt B, et al. Analysis of the human neurexin genes: alternative splicing and the generation of protein diversity. Genomics 9, 587-597 (2002).
61. Hannon GJ. RNA interference. Nature 418, 244-251 (2002). Good review.
62. Ahlquist P. RNA-depenedent RNA polymerases, viruses, and RNA silencing. Science 296 1270-1273 (2002). Good review.
63. Lai EC. Micro RNAs are complementary to 3′UTR sequence motifs that mediate negative post-transcriptional regulation. Nature Genet. 30, 363-364 (2002).
64. Mattick JS. Non coding RNAs: the architects of eukaryotic complexity. EMBO Rep 2, 986-991 (2001).
65. Neubauer G, King A, Rappsilber J, et al. Mass spectrometry and EST-database searching allows characterization of the multiprotein spliceosome complex. Nature Genet. 20, 46-50 (1998).
66. Emmert-Buck MR, Gillespie JW, Paweletz CP, et al. An approach to proteomic analysis of human tumors. Mol. Carcinog. 27, 158-165 (2000).
67. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer Lancet 359, 572-577 (2002).
68. Petricoin EF, Ornstein DK, Paweletz CP et al. Serum proteomic patterns for detection of prostate cancer. J. Natl Cancer Inst. 94, 1576-1578 (2002).
69. Cazares LH, Adam BL, Ward MD et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin. Cancer Res. 8, 2541-2552 (2002).
70. Chen G, Gharib TG, Huang CC et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin. Cancer Res. 7, 2298-2305 (2002).
71. Hanash S, Brichory F, Beer D. A proteomic approach to the identification of lung cancer markers. Dis. Markers. 4, 295-300 (2001).
72. Oh JMC, Brichory F, Puravs E et al. A database of protein expression in lung cancer. Proteomics 1, 1303-1319 (2001).
73. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct profiles specific for lung tumors and premalignant lung lesions by SELDI mass spectrometry. Proceedings 93rd Annual AACR Meeting. CA, USA, 36 (2002).
74. Adam BL, Vlahou A, Semmes OJ, Wright GL Jr. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 1, 1264-1270 (2001).
75. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 1, 683-695 (2002). Good review.
76. Valle RPC, Chavany C, Hernandez-Gonzalez R, Jendoubi M. Linking proteins to disease. Current Drug Discovery 5, 35-39 (2002). Review of ANTIBIOMIX™ approach.
77. Marchetti A, Bertacca G, Buttitta F, et al. Telomerase activity as a prognostic indicator in stage I NSCLC. Clin. Cancer Res. 5(8), 2077-2081 (1999).
78. Proteomics Public-Private Group Maps Out Initiatives, (HUPO), Science News, Science 296, 827 (2002).